TcrossGlobal

Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: The ONCO PE Trial

The ONCO PE trial demonstrated that in cancer patients with low-risk pulmonary embolism, 18 months of treatment with rivaroxaban significantly reduced the risk of recurrent venous thromboembolism (VTE) compared with 6 months of treatment, while not significantly increasing the risk of bleeding, according to a study presented by Dr. Yugo Yamashita, Kyoto University, Japan, in the Featured Science session at AHA Scientific Sessions 2024.

Cancer patients often undergo CT scans for cancer evaluation, during which incidental low-risk pulmo...

Continue reading this article

Select an option below:

Free Registration
Already have an account?
Log In

Introducing the main contents

Conference Reports

Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!

Complex PCI Cases

Features case reports on patients with complex lesions encountered in daily clinical practice.

Live Demonstration CoursesComing soon

In this section you will find live videos of catheter interventions for complex lesions.

What is TCROSS NEWS GLOBAL?

TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.

Learn more about TCROSS NEWS Global

This website is automatically translated using Google Translate.